menu
    • menu

    Company profile for Ever Pharma

    Ever Pharma-PSE
    News
    EVER Pharma Gained EU-Approval of Testosterone Enantate

    19 Aug 2024

    // PRESS RELEASE

    EVER Pharma gained EU-Approval for Advanced Cancer Treatment

    16 Apr 2024

    // PRESS RELEASE

    EVER Pharma Announces Approval of Testosterone Undecanoate in the EU

    13 Mar 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Ever Pharma RM

    Contact Supplier

    Website

    Contract Pharma

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/i9XL-1ZrZZM

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Related CompaniesRelated Companies

    About

    EVER Pharma is a fully integrated specialty pharmaceuticals company focused on the research, development, production, and commercialization of products in the areas of neurology and specialty injectables, covering oncology, intensive care and hormone therapeutics. From our headquarters in Austria, we run a dynamic operation providing innovative products and value-added formulations aimed at enhancing the lives of patients and supporting the work of healthcare professionals through improved convenience and safety.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ever PharmaAustria Flag
    Country
    Country
    Austria
    Address
    Address
    Oberburgau 3, 4866 Unterach
    Telephone
    Telephone
    +43 7665205550
    Client Email
    Email
    cdmo@everpharma.com
    Client Website
    Website
    https://www.everpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ever-neuro-pharma/
    youtube
    YouTube
    https://www.youtube.com/@everpharmafrance70/videos
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI South East Asia

    Not Confirmed

    envelop Contact Supplier

    CPhI South East Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/ever-pharma-party-content-39961.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/ever-pharma-party-content-46564.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3358

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    EVER Pharma Gained EU-Approval of Testosterone Enantate
    EVER Pharma Gained EU-Approval of Testosterone Enantate

    19 Aug 2024

    // PRESS RELEASE

    https://www.everpharma.com/news/ever-pharma-gained-eu-approval-of-testosterone-enantate/

    PRESS RELEASE
    19 Aug 2024
    Share Share
    EVER Pharma gained EU-Approval for Advanced Cancer Treatment
    EVER Pharma gained EU-Approval for Advanced Cancer Treatment

    16 Apr 2024

    // PRESS RELEASE

    https://www.everpharma.com/news/ever-pharma-gained-eu-approval-for-advanced-cancer-treatment/

    PRESS RELEASE
    16 Apr 2024
    Share Share
    EVER Pharma Announces Approval of Testosterone Undecanoate in the EU
    EVER Pharma Announces Approval of Testosterone Undecanoate in the EU

    13 Mar 2024

    // PRESS RELEASE

    https://www.everpharma.com/news/ever-pharma-announces-approval-of-testosterone-undecanoate-in-the-eu/

    PRESS RELEASE
    13 Mar 2024
    Share Share
    EVER Pharma gains EU Marketing Authorization for Trabectedin
    EVER Pharma gains EU Marketing Authorization for Trabectedin

    22 Jun 2023

    // PRESS RELEASE

    https://www.everpharma.com/news/ever-pharma-gains-eu-marketing-authorization-for-trabectedin/

    PRESS RELEASE
    22 Jun 2023
    Share Share
    EVER Pharma Expands Operations with Opening of New Mfg Facility , Germany
    EVER Pharma Expands Operations with Opening of New Mfg Facility , Germany

    10 Mar 2023

    // PRESS RELEASE

    https://www.everpharma.com/news/ever-pharma-expands-operations-with-opening-of-new-manufacturing-facility-in-jena-germany/

    PRESS RELEASE
    10 Mar 2023
    Share Share
    EVER Pharma receives EU approval for liquid ready to use Bortezomib formulation
    EVER Pharma receives EU approval for liquid ready to use Bortezomib formulation

    02 Sep 2022

    // PRESS RELEASE

    https://www.everpharma.com/news/ever-pharma-receives-eu-approval-for-a-liquid-ready-to-use-bortezomib-formulation/

    PRESS RELEASE
    02 Sep 2022
    Share Share

    Services

    Discover the service capabilities from this company

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Ever Pharma popup full-view
    Sterile Injectable Manufacturing
    full-view
    Injectable Suspensions
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    EDQM

    read-more
    read-more

    01

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : DE_TH_01H_G...

    EudraGMDP Key : 170740

    Country : Germany

    Issue Date : 2024-07-02

    Post Code :

    NCA Ref : 217688171996...

    City : Jena

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : DE_TH_01H_G...

    EudraGMDP Key : 170739

    Country : Germany

    Issue Date : 2024-07-02

    Post Code :

    NCA Ref : 217687171996...

    City : Jena

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482167-1418...

    EudraGMDP Key : 150878

    Country : Austria

    Issue Date : 2021-12-22

    Post Code :

    NCA Ref : 482167

    City : Ebensee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482197-1418...

    EudraGMDP Key : 143779

    Country : Austria

    Issue Date : 2021-12-22

    Post Code :

    NCA Ref : 482197

    City : Unterach am Attersee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482197-0045

    EudraGMDP Key : 52731

    Country : Austria

    Issue Date : 2019-02-04

    Post Code :

    NCA Ref : 482197

    City : Unterach am Attersee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482167-0009

    EudraGMDP Key : 52732

    Country : Austria

    Issue Date : 2018-11-20

    Post Code :

    NCA Ref : 482167

    City : Ebensee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482197-0028

    EudraGMDP Key : 34259

    Country : Austria

    Issue Date : 2015-12-03

    Post Code :

    NCA Ref : 482197

    City : Unterach am Attersee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482197-0025

    EudraGMDP Key : 24478

    Country : Austria

    Issue Date : 2014-06-26

    Post Code :

    NCA Ref : 482197

    City : Unterach am Attersee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482197-0011

    EudraGMDP Key : 21346

    Country : Austria

    Issue Date : 2013-09-11

    Post Code :

    NCA Ref : 482197

    City : Unterach am Attersee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    10

    GMP Certified

    EU
    arrow
    Contract Pharma
    Attending

    Ever Pharma

    Type : GMP Certificates

    Number : 482167-0004

    EudraGMDP Key : 15764

    Country : Austria

    Issue Date : 2012-09-25

    Post Code :

    NCA Ref : 482167

    City : Ebensee

    Ever Pharma CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact EVER Neuro Pharma GmbH and get a quotation

    EVER Neuro Pharma GmbH is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of Pig brain peptide bulk offered by EVER Neuro Pharma GmbH

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search